Mice undergoing this treatment displayed ovarian cysts, increased testosterone levels, and reduced ovarian aromatase expression.[73] These studies[42, 73] allowed us to confirm at the preclinical level the efficacy of myo‐inositol and D‐chiro‐inositol in treating PCOS but highlighted the need for specific combined formulations containing low dosages of D‐chiro‐inositol, underscoring the importance of carefully evaluating treatments of PCOS patients with D‐chiro‐inositol at high doses or for prolonged times. Here, CYP19A1 is linked to polycystic ovary syndrome.